scholarly journals S783 Increased Risk of Hospitalization, Surgery and Venous Thromboembolism Among Patients With Inflammatory Bowel Disease and Malnutrition in a Large, Community-Based Healthcare System

2021 ◽  
Vol 116 (1) ◽  
pp. S364-S364
Author(s):  
Liat Gutin ◽  
Shiyun Zhu ◽  
Aida Shirazi ◽  
Jeffrey Lee ◽  
Fernando Velayos
2007 ◽  
Vol 133 (4) ◽  
pp. 1106-1112 ◽  
Author(s):  
Uma Mahadevan ◽  
William J. Sandborn ◽  
De–Kun Li ◽  
Shahbaz Hakimian ◽  
Sunanda Kane ◽  
...  

2021 ◽  
Vol 160 (6) ◽  
pp. S-146
Author(s):  
Renz Klomberg ◽  
Martine Aardoom ◽  
Polychronis Kemos ◽  
Frank Ruemmele ◽  
C.H. (Heleen) Van Ommen ◽  
...  

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 4708-4708
Author(s):  
Nicole Kucine ◽  
Victoria Cooley ◽  
Fisnik Prishtina ◽  
Linda M Gerber ◽  
Kimberley A Chien

Introduction: Venous thromboembolism (VTE) is a known complication in children with inflammatory bowel disease (IBD) and can be associated with significant morbidity and mortality. Central lines, inflammation, hospital stays, and protein losses are among risk factors that contribute to this elevated risk. While it is known that children with IBD have an increased VTE risk, there are no standard guidelines for prevention of this unwanted complication. Decreasing the rate of hospital-acquired VTE in all hospitalized children is of national interest, especially in this unique patient population. However, there are no clear data regarding the true impact of VTE on the pediatric IBD population to guide practitioners in prevention and management. Given that IBD patients are known to have an increased risk of VTE, we sought to assess the burden associated with VTE development in hospitalized IBD patients. Methods: The Pediatric Health Information System database (PHIS), a database that includes both clinical and resource utilization data for over 45 children's hospitals, was utilized to gather inpatient data from 2009-2017. ICD9 (IBD - 555.xx, 556.xx and VTE - 325, 415.1x, 451.x, 452, 453.0-.9, and 572.1) and ICD10 (IBD - K50.0-.919, K51.0-.919 and VTE - I80.0-.9, I81, I82.0-.91, I63.6, I67.6) diagnostic codes for IBD and VTE were applied to identify hospitalized IBD patients who experienced a VTE event. First admissions during the time period were used to avoid capturing the same VTE event more than once. Demographic data, as well as data regarding hospitalization, were reviewed. The Institutional Review Board of Weill Cornell Medicine approved this study. Results: 19,004 first admissions were identified for patients with IBD. Of those, 475 had documented episodes of VTE, demonstrating an incidence of having a VTE at first admission of 2.5%. There were no significant differences in gender, age at first admission, ethnicity, or geographic region between hospitalized IBD patients who did and did not have a VTE event. Hospitalized IBD patients with VTE had a significantly greater median length of stay, significantly higher likelihood of ICU stay, and a significantly higher discharge mortality rate (Table 1). Children with IBD and VTE had an odds ratio of 8.63 [95% CI 7.02-10.62, p=<0.001] for ICU stay, and an odds ratio of 6.14 [95% CI 2.76-13.69, p=<0.001] for discharge mortality compared to children with IBD and no VTE. Median billed charges and total costs were significantly higher in the hospitalized IBD patients with VTE compared to those without VTE - both were approximately 3 times greater in IBD patients who developed a VTE (Table 2). When looking at the annual incidence rate of VTE among hospitalized IBD patients for first admission, rates ranged from 1.7 to 3.4 per 100 patients, with an average number of cases of 53 per year (Figure 1). Conclusion: Our data demonstrate that hospitalized children with IBD and a VTE event are at greater risk for mortality and increased likelihood of ICU stay than those without VTE. They are also shown to incur significantly higher hospital costs when compared to children without a VTE episode. Our study is limited due to the possibility of missing data due to coding errors, which can occur in large database studies such as this. Despite this limitation, our data demonstrate that a significant medical and financial burden is placed on hospitalized children with IBD who develop a VTE. Our evidence, and the work of others, support the need for larger, prospective, multi-center studies focused on prevention of VTE in hospitalized pediatric IBD patients. Disclosures Cooley: off-label: Other: drug use.


Author(s):  
Kate E Lee ◽  
Francesca Lim ◽  
Jean-Frederic Colombel ◽  
Chin Hur ◽  
Adam S Faye

Abstract Background Patients with inflammatory bowel disease (IBD) have a 2- to 3-fold greater risk of venous thromboembolism (VTE) than patients without IBD, with increased risk during hospitalization that persists postdischarge. We determined the cost-effectiveness of postdischarge VTE prophylaxis among hospitalized patients with IBD. Methods A decision tree compared inpatient prophylaxis alone vs 4 weeks of postdischarge VTE prophylaxis with 10 mg/day of rivaroxaban. Our primary outcome was quality-adjusted life years (QALYs) over 1 year, and strategies were compared using a willingness to pay of $100,000/QALY from a societal perspective. Costs (in 2020 $USD), incremental cost-effectiveness ratios (ICERs) and number needed to treat (NNT) to prevent 1 VTE and VTE death were calculated. Deterministic 1-way and probabilistic analyses assessed model uncertainty. Results Prophylaxis with rivaroxaban resulted in 1.68-higher QALYs per 1000 persons compared with no postdischarge prophylaxis at an incremental cost of $185,778 per QALY. The NNT to prevent a single VTE was 78, whereas the NNT to prevent a single VTE-related death was 3190. One-way sensitivity analyses showed that higher VTE risk &gt;4.5% and decreased cost of rivaroxaban ≤$280 can reduce the ICER to &lt;$100,000/QALY. Probabilistic sensitivity analyses favored prophylaxis in 28.9% of iterations. Conclusions Four weeks of postdischarge VTE prophylaxis results in higher QALYs compared with inpatient prophylaxis alone and prevents 1 postdischarge VTE among 78 patients with IBD. Although postdischarge VTE prophylaxis for all patients with IBD is not cost-effective, it should be considered in a case-by-case scenario, considering VTE risk profile, costs, and patient preference.


2019 ◽  
Vol 26 (9) ◽  
pp. 1394-1400 ◽  
Author(s):  
Adam S Faye ◽  
Kenneth W Hung ◽  
Kimberly Cheng ◽  
John W Blackett ◽  
Anna Sophia Mckenney ◽  
...  

Abstract Background Despite increased risk of venous thromboembolism (VTE) among hospitalized patients with inflammatory bowel disease (IBD), pharmacologic prophylaxis rates remain low. We sought to understand the reasons for this by assessing factors associated with VTE prophylaxis in patients with IBD and the safety of its use. Methods This was a retrospective cohort study conducted among patients hospitalized between January 2013 and August 2018. The primary outcome was VTE prophylaxis, and exposures of interest included acute and chronic bleeding. Medical records were parsed electronically for covariables, and logistic regression was used to assess factors associated with VTE prophylaxis. Results There were 22,499 patients studied, including 474 (2%) with IBD. Patients with IBD were less likely to be placed on VTE prophylaxis (79% with IBD, 87% without IBD), particularly if hematochezia was present (57% with hematochezia, 86% without hematochezia). Among patients with IBD, admission to a medical service and hematochezia (adjusted odds ratio 0.27; 95% CI, 0.16–0.46) were among the strongest independent predictors of decreased VTE prophylaxis use. Neither hematochezia nor VTE prophylaxis was associated with increased blood transfusion rates or with a clinically significant decline in hemoglobin level during hospitalization. Conclusion Hospitalized patients are less likely to be placed on VTE prophylaxis if they have IBD, and hematochezia may drive this. Hematochezia appeared to be minor and was unaffected by VTE prophylaxis. Education related to the safety of VTE prophylaxis in the setting of minor hematochezia may be a high-yield way to increase VTE prophylaxis rates in patients with IBD.


Sign in / Sign up

Export Citation Format

Share Document